Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifampicin added to standard antibiotics for community-acquired pneumococcal pneumonia
NL-OMON22991Phase 4Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rifampicin in community-acquired pneumonia (CAP) and Pneumococcal pneumonia (PP) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Lipoteichoic acid in serum and urine. Started Jan 2013; status: active, not recruiting.
02
Drugs
rifampicin
03
Conditions
community-acquired pneumonia (CAP)Pneumococcal pneumonia (PP)
Beyond the preview
Go deeper on NL-OMON22991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22991.